Hsu Jason's Form 4 filing

Immix Biopharma, Inc. (IMMX) · filed Jul 31, 2024

Accession no.: 0001493152-24-029810
Filed: Jul 31, 2024
Trade date: Jul 18-24, 2024
Filing delay: 13 daysLate
Rule 10b5-1 plan: Not checked

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market purchases total $19.5K. It was filed 13 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Hsu JasonCIK 0001895035	Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Jul 18, 2024	Common Stock	PPurchaseAcquired	+3,200	$2.07^F1	+$6,624	816,200	Direct
Jul 24, 2024	Common Stock	PPurchaseAcquired	+6,000	$2.15^F2	+$12,900	822,200	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

This transaction was executed in multiple trades at prices ranging from $2.06 to $2.07576, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

This transaction was executed in multiple trades at prices ranging from $2.1191 to $2.166, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Remarks

See Power of Attorney filed as Exhibit 24.1 to the Form 3 filed by the Reporting Person on December 15, 2021.

Read the full filing on SEC EDGAR (opens in a new tab)